Holen Sie sich die Stockscreener-App
28.11
1.18%
-0.335
Schlusskurs vom Vortag:
$28.45
Offen:
$27.7
24-Stunden-Volumen:
206.03K
Relative Volume:
0.20
Marktkapitalisierung:
$3.69B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-4.08%
1M Leistung:
+5.22%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$27.04
$28.61
1-Wochen-Bereich:
$26.00
$29.50
52-Wochen-Spanne:
$12.30
$37.99
Metsera Inc Stock (MTSR) Company Profile
Firmenname
Metsera Inc
Sektor
Branche
Telefon
(212) 784-6595
Adresse
3 WORLD TRADE CENTER, NEW YORK
Vergleichen Sie MTSR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
28.15 | 3.69B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.83 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.21 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.46 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.60 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-25 | Eingeleitet | BofA Securities | Buy |
| 2025-02-25 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-25 | Eingeleitet | Guggenheim | Buy |
Metsera Inc Aktie (MTSR) Neueste Nachrichten
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results - MSN
Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results - Investing.com Nigeria
Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha
Cantor Fitzgerald Predicts Metsera FY2026 Earnings - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
RFK Axes CDC Vaccine Advisors; Metsera’s Weight Loss Win; FDA Supports CGT - BioSpace
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Metsera Shows Rising Price Performance With Jump To 92 RS Rating - Investor's Business Daily
Metsera (NASDAQ:MTSR) Price Target Raised to $62.00 at Guggenheim - Defense World
Metsera (NASDAQ:MTSR) Shares Gap Up Following Analyst Upgrade - Defense World
Metsera stock extends gains on obesity drug data (MTSR:NASDAQ) - Seeking Alpha
Metsera’s obesity candidate ‘comparable to leading GLP-1-based medicines’ - The Pharma Letter
Metsera price target raised to $62 from $56 at Guggenheim - TipRanks
Metsera CEO to Present Obesity Drug Pipeline at Goldman Sachs Healthcare Conference | MTSR Stock News - Stock Titan
Metsera Hits New High As Obesity Pipeline Gains Weight - RTTNews
Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Metsera chasing best-in-class profile with amylin program - biocentury.com
Metsera reports promising Phase 1 trial results for obesity treatment By Investing.com - Investing.com South Africa
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i - GlobeNewswire
Metsera’s Amylin Analog Stars In Obesity Phase I - insights.citeline.com
Obesity treatment startup Metsera rises on positive trial results - Sherwood News
metsera reports positive phase 1 trial results for obesity drug - Investing.com Australia
Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump - Investor's Business Daily
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes By Stocktwits - Investing.com India
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial - MSN
Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med - MedCity News
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data - Benzinga
Metsera obesity monotherapy data ‘looks competitive,’ says BofA - TipRanks
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes - MSN
Metsera shares climb on early data for amylin-targeting obesity shot - BioPharma Dive
Warner Bros. Discovery, Metsera, eToro Group And Other Big Stocks Moving Higher On Monday - Benzinga
Metsera's Phase 1 Trial of MET-233i Shows Weight Reduction With no Severe Adverse Events - marketscreener.com
Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks - BioSpace
Metsera’s drug shows potential in early clinical trial - statnews.com
metsera reports positive phase 1 trial results for obesity drug By Investing.com - Investing.com Canada
Metsera shares soar on positive amylin candidate trial results By Investing.com - Investing.com Nigeria
Metsera shares soar on positive amylin candidate trial results - Investing.com Australia
Metsera announces topline data from Phase 1 trial of MET-233i - TipRanks
Metsera, Inc. Reports Positive Phase 1 Trial Results - TipRanks
Obesity Startup Metsera Shares Rise on Early-Stage Trial Results - Bloomberg.com
Metsera reports promising Phase 1 trial results for obesity treatment - Investing.com
Metsera’s amylin drug shows early potential for substantial weight loss - statnews.com
Weight Loss Drug Shows 8.4% Reduction in Phase 1 Trial, Monthly Dosing Success | MTSR Stock News - Stock Titan
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association® - The Manila Times
Metsera to Present New Research Highlighting the Breadth - GlobeNewswire
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association - TradingView
Next-Gen Monthly Obesity Drug Shows Promise: Metsera to Present Breakthrough Clinical Data at ADA 2025 - Stock Titan
Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership - insights.citeline.com
Finanzdaten der Metsera Inc-Aktie (MTSR)
Es liegen keine Finanzdaten für Metsera Inc (MTSR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Metsera Inc-Aktie (MTSR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
1.21%
2.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):